Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders

NCT ID: NCT03275766

Last Updated: 2021-05-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-01

Study Completion Date

2019-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Psychomotor slowing may occur in major psychiatric disorders, such as major depressive disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills, motor planning and gross motor behavior. In major depression and schizophrenia, psychomotor slowing is associated with alterations of premotor cortex, dorsolateral prefrontal cortex and basal ganglia. This randomized, sham-controlled, prospective trial will test, whether 15 sessions of repetitive transcranial magnetic stimulation (rTMS) may ameliorate psychomotor slowing in schizophrenia or major depression.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Psychomotor slowing may occur in major psychiatric disorders, such as major depressive disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills, motor planning and gross motor behavior. In major depression and schizophrenia, psychomotor slowing is associated with alterations of premotor cortex, dorsolateral prefrontal cortex and basal ganglia. This randomized, sham-controlled, prospective trial will test, whether 15 sessions of rTMS in 3 weeks may ameliorate psychomotor slowing in schizophrenia or major depression.

Eligible participants will be randomized to one of four arms:

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psychomotor Retardation Psychomotor Slowing Schizophrenia and Related Disorders Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors
double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DLPFC facilitatory

repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC

usually effective in depression treatment, probably no specific effect on psychomotor slowing

Group Type ACTIVE_COMPARATOR

DLPFC facilitatory

Intervention Type OTHER

15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli

preSMA/SMA inhibitory

repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA

should inhibit overactive premotor cortices

Group Type EXPERIMENTAL

SMA inhibitory

Intervention Type OTHER

1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli

preSMA/SMA facilitatory

intermittend theta burst stimulation (iTBS) over preSMA/SMA

should facilitate neural activity within premotor cortices

Group Type EXPERIMENTAL

SMA facilitatory

Intervention Type OTHER

Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli

sham TMS

sham rTMS with a placebo coil over occipital cortex

should have no effect at all (no transcranial magnetic stimulation, only sound)

Group Type SHAM_COMPARATOR

sham TMS

Intervention Type OTHER

Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DLPFC facilitatory

15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli

Intervention Type OTHER

SMA inhibitory

1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli

Intervention Type OTHER

SMA facilitatory

Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli

Intervention Type OTHER

sham TMS

Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

rTMS facilitatory DLPFC rTMS inhibitory SMA iTBS facilitatory SMA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* suffering from major depressive disorder or schizophrenia spectrum disorder according to DSM-5 criteria
* right handedness
* normal or corrected-to-normal vision and hearing

Exclusion Criteria

* epilepsy
* history of severe head trauma
* current abuse of drugs or alcohol; past addiction to drugs or alcohol
* pregnancy
* incompatibility to cerebral MRI
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Bern

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sebastian Walther

Prof. Dr., Head of the outpatient clinic, University Hospital of Psychiatry

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sebastian Walther, MD

Role: PRINCIPAL_INVESTIGATOR

University of Bern, University Hospital of Psychiatry

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Psychiatry, University of Bern

Bern, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SNCTP610

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

rTMS in First Episode Psychosis
NCT02131129 COMPLETED NA